{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:46:32Z","timestamp":1793195192410,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French Ministry of Health"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a randomized open-labeled phase 2 study of the immunogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD. The proportion of responders (4-fold increase in serotype-specific immunoglobulin [Ig] G antibodies) to \u226510 shared serotypes was assessed at week 8. Secondary end points were (1) geometric mean titers, (2) responders to 0\u20131, 2\u20135, 6\u20139, or 10\u201312 serotypes, (3) pneumococcal opsonophagocytic activity, and (4) response durability at weeks 24 and 96.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 128 patients were randomized in the PCV13\/PPSV23 (n = 63) or PPSV23-alone groups (n = 65). At week 8, 24.56% and 8.20% of patients from the PCV13\/PPSV23 and PPSV23 groups, respectively, reached the primary end point (P = .02). These numbers were 36.2% and 8.7% for opsonophagocytic activity responders (P = .002). A combined PCV13\/PPSV23 strategy improved the breadth of responses to 0\u20131, 2\u20135, 6\u20139, or 10\u201312 serotypes with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group. At week 96, geometric mean titers were significantly higher in the PCV13\/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A PCV13\/PPSV23 regimen improved the breadth and magnitude of antibody responses against a large range of pneumococcal serotypes in adults with SCD. The sustainability of the immune response requires recall strategies.<\/jats:p>\n                  <jats:p>Clinical Trial Registration: NCT02274415<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad037","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T21:33:03Z","timestamp":1674595983000},"page":"1949-1958","source":"Crossref","is-referenced-by-count":8,"title":["Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial"],"prefix":"10.1093","volume":"76","author":[{"given":"Giovanna","family":"Melica","sequence":"first","affiliation":[{"name":"Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP , Creteil , France"},{"name":"Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bartolucci","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Audureau","sequence":"additional","affiliation":[{"name":"Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[{"name":"Clinical Investigation Center 1430, Inserm, Henri Mondor Hospital, APHP , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Habibi","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Gellen","sequence":"additional","affiliation":[{"name":"Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Selmane","sequence":"additional","affiliation":[{"name":"Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Henri Mondor Hospital, APHP , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lacabaratz","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Levy","sequence":"additional","affiliation":[{"name":"Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP , Creteil , France"},{"name":"Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est , Creteil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"2023060818544616600_ciad037-B1","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N Engl J Med"},{"key":"2023060818544616600_ciad037-B2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease: cooperative study of sickle cell disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"key":"2023060818544616600_ciad037-B3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"key":"2023060818544616600_ciad037-B4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJM196910232811703","article-title":"Functional asplenia in sickle-cell anemia","volume":"281","author":"Pearson","year":"1969","journal-title":"N Engl J Med"},{"key":"2023060818544616600_ciad037-B5","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2009.03.010","article-title":"Infection in sickle cell disease: a review","volume":"14","author":"Booth","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2023060818544616600_ciad037-B6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0031-3955(05)70426-0","article-title":"Sickle cell disease","volume":"43","author":"Lane","year":"1996","journal-title":"Pediatr Clin North Am"},{"key":"2023060818544616600_ciad037-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/adc.57.5.343","article-title":"Defective yeast opsonisation and functional deficiency of complement in sickle cell disease","volume":"57","author":"Larcher","year":"1982","journal-title":"Arch Dis Child"},{"issue":"suppl 5S","key":"2023060818544616600_ciad037-B8","doi-asserted-by":"crossref","first-page":"1399S","DOI":"10.1093\/jn\/130.5.1399S","article-title":"The dynamic link between the integrity of the immune system and zinc status","volume":"130","author":"Fraker","year":"2000","journal-title":"J Nutr"},{"key":"2023060818544616600_ciad037-B9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.iy.13.040195.003255","article-title":"T cell-independent antigens type 2","volume":"13","author":"Mond","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"2023060818544616600_ciad037-B10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jama.1993.03510150060030","article-title":"Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations","volume":"270","author":"Butler","year":"1993","journal-title":"JAMA"},{"key":"2023060818544616600_ciad037-B11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023060818544616600_ciad037-B12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J Pediatr"},{"issue":"4 pt 1","key":"2023060818544616600_ciad037-B13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.101.4.604","article-title":"Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants","volume":"101","author":"Rennels","year":"1998","journal-title":"Pediatrics"},{"key":"2023060818544616600_ciad037-B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"2023060818544616600_ciad037-B15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1542\/peds.106.5.965","article-title":"Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease","volume":"106","author":"O\u2019Brien","year":"2000","journal-title":"Pediatrics"},{"key":"2023060818544616600_ciad037-B16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"2023060818544616600_ciad037-B17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jpeds.2010.11.025","article-title":"Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure","volume":"158","author":"McCavit","year":"2011","journal-title":"J Pediatr"},{"key":"2023060818544616600_ciad037-B18","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1086\/598324","article-title":"Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2023060818544616600_ciad037-B19","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/QAD.0b013e3282887e91","article-title":"Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults","volume":"21","author":"Lesprit","year":"2007","journal-title":"AIDS"},{"key":"2023060818544616600_ciad037-B20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","article-title":"A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults","volume":"362","author":"French","year":"2010","journal-title":"N Engl J Med"},{"key":"2023060818544616600_ciad037-B21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023060818544616600_ciad037-B22","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.vaccine.2021.02.069","article-title":"Invasive pneumococcal disease in Canada 2010\u20132017: the role of current and next-generation higher-valent pneumococcal conjugate vaccines","volume":"39","author":"Dion","year":"2021","journal-title":"Vaccine"},{"key":"2023060818544616600_ciad037-B23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QAI.0000000000002916","article-title":"Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among adults with HIV-United States, 2008\u20132018","volume":"90","author":"Kobayashi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023060818544616600_ciad037-B24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pbc.25502","article-title":"13-Valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6\u201317 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study","volume":"62","author":"De Montalembert","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2023060818544616600_ciad037-B25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1600-6143.2007.01668.x","article-title":"Immunogenicity of pneumococcal vaccine in renal transplant recipients\u2014three year follow-up of a randomized trial","volume":"7","author":"Kumar","year":"2007","journal-title":"Am J Transplant"},{"key":"2023060818544616600_ciad037-B26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/506356","article-title":"Association of polymorphisms of IGF1R and genes in the transforming growth factor\u2013\u03b2 bone morphogenetic protein pathway with bacteremia in sickle cell anemia","volume":"43","author":"Adewoye","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad037\/50113802\/ciad037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1949\/50541670\/ciad037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1949\/50541670\/ciad037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:55:54Z","timestamp":1686250554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/11\/1949\/7006790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad037","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,27]]}}}